Management and treatment of relapsed or refractory Ph(-) B-precursor ALL: a web-based, double-blind survey of EU clinicians.

ABSTRACT:

Background

The prognosis for adult patients with Ph(-) B-precursor acute lymphoblastic leukaemia (ALL) who are refractory to treatment or experience relapse (R/R), is poor; over 90% of these patients die from the disease, typically within a few months. While there are some national guidelines published for the treatment of adult patients with ALL, and local working group recommendations do exist, there is very little detail and no preferred treatment regimens for adult patients with R/R Ph(-) B-precursor ALL. The aim of this study was to describe current real-world clinical practice in Europe for the management and treatment of adult R/R Ph(-) B-precursor ALL.

Methods

A web-based, double-blind survey was conducted in November/December 2013 in France, Germany, Italy, Spain, a

SUBMITTER: Saltman D 

PROVIDER: S-EPMC4619337 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature